AUTOLOGOUS DC-CIK CELL THERAPY IN PATIENTS WITH ADVANCED BLADDER CANCER: TREATMENT AND NURSING OUTCOMES

Lang Wang^{1, 2}, Qian Zhou^{1, 2}, Xiaoxi Tan^{1, 2}, Ziyuan Wu^{1, 2}, Chan Fu^{1, 2}, Yun Liu^{1, 2}, Bo Zhang^{1, 3, *}

¹Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, PR China - ²Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, PR China - ³Department of Health Management Center, The Second Xiangya Hospital, Central South University, Changsha, PR China

Objective: About 150,000 people die from bladder cancer every year, making it the ninth most common cancer in the world. It is characterized by local invasion, easy metastasis and a high recurrence rate and is a severe threat to human health. This study was designed to investigate the treatment of advanced bladder cancer with DC-CIK cell therapy, including treatment outcomes and satisfaction and compliance with nursing care in patients undergoing the treatment. 

Methods: In this study, 20 patients with advanced bladder cancer were treated with DC-CIK cell therapy plus chemotherapy or chemotherapy alone. Treatment outcomes were assessed after 1, 2 and 3 years. Subsequently, we performed a retrospective chart analysis of changes in T cell subsets, treatment efficacy, overall survival rate, disease-free survival rate, patient compliance with treatment and satisfaction with nursing care. 

Results: Autologous DC-CIK cells plus chemotherapy were significantly more effective in the treatment of advanced bladder cancer than chemotherapy alone. The disease control rate was 57.5% in the experimental group and 85% in the control group. 

Conclusion: Careful nursing and observation and timely treatment of adverse reactions after treatment can significantly improve patients' symptoms as well as their and their family's satisfaction.